A randomized control trial of six months low-dose erythromycintreatment for Chronic Obstructive Pulmonary Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000367

Enrollment

Unknown

Registered

2009-04-04

Start date

2008-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Group B:Routine treatment

Group A:Erythromycin 125 mg orally taken three times per day+routine treatment.

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 80 years old; 2. moderate to severe COPD with FEV1 between 30% and 70% predicted,and FEV1/FVC < 70%; 3. FEV1 reversibility of less than 15% and/or less than 200ml to beta-agonists.

Exclusion criteria

Exclusion criteria: 1. Patients have a history of asthma, bronchiectasis, neoplasia or other significant respiratory disease, unstable systemic organ statu and malignant; 2. A history of macrolide allergy or a history of hepatic impairment defined as abnormal liver function tests.

Design outcomes

Primary

Measure	Time frame
Neutrophil elastase level;Acute exacerbation;Quality of life;the number of inflammatory cells and and it's percentages;	—

Secondary

Measure	Time frame
Lung function;6 minute walk distance;	—

Countries

China

Contacts

Public ContactXiaoning Zhong

xnzhong101@sina.com+86 0 13607881203

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026